Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Tanja D de Gruijl"'
Autor:
Henk M.W. Verheul, Tanja D. de Gruijl, Marco B. Polee, Paul Hamberg, Charlotte M. Huijts, Maartje Los, Inge M. Werter, Sinéad. M. Lougheed, Hans van Vliet, John B. A. G. Haanen, Helgi H. Helgason, Metin Tascilar
Publikováno v:
Werter, I M, Huijts, C M, Lougheed, S M, Hamberg, P, Polee, M B, Tascilar, M, Los, M, Haanen, J B A G, Helgason, H H, Verheul, H M, de Gruijl, T D, van der Vliet, H J & Dutch WIN-O Consortium 2019, ' Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus ', Cancer Immunology, Immunotherapy, vol. 68, no. 5, pp. 787-798 . https://doi.org/10.1007/s00262-019-02313-z
Cancer Immunology, Immunotherapy, 68(5), 787-798. Springer Science and Business Media Deutschland GmbH
Cancer Immunology Immunotherapy, 68, 5, pp. 787-798
Cancer immunology, immunotherapy, 68(5), 787-798. Springer Science and Business Media Deutschland GmbH
Cancer Immunology Immunotherapy, 68, 787-798
Cancer Immunology, Immunotherapy, 68(5), 787-798. Springer Science and Business Media Deutschland GmbH
Cancer Immunology Immunotherapy, 68, 5, pp. 787-798
Cancer immunology, immunotherapy, 68(5), 787-798. Springer Science and Business Media Deutschland GmbH
Cancer Immunology Immunotherapy, 68, 787-798
Contains fulltext : 207393.pdf (Publisher’s version ) (Open Access) INTRODUCTION: Metastatic renal cell cancer (mRCC) patients have a median overall survival (mOS) of approximately 28 months. Until recently, mammalian target of rapamycin (mTOR) inh